Genscript Biotech Corporation

(*Incorporated in the Cayman Islands with limited liability*)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
LEGEND ANNOUNCES PRESENTATIONS AT THE 2025 ASH ANNUAL MEETING

This is a voluntary announcement made by Genscript Biotech Corporation (the "**Company**").

The board of directors (the "**Board**") of the Company is pleased to announce that Legend Biotech Corporation ("**Legend**"), an associate of the Company, whose shares are listed by way of American Depository Shares on the Nasdaq Global Select Market in the United States, has issued a press release on 6 December 2025 (New York time) announcing new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed/refractory multiple myeloma (RRMM) patients from one oral presentation and updated results from the Phase 3 CARTITUDE-4 study at the 2025 American Society of Hematology ("**ASH**") Annual Meeting. Subgroup durability data and real-world outcomes with CARVYKTI® were also presented from six poster presentations. Moreover, Legend also presented first-in-human data from the dual-targeted allogeneic CAR-T candidate, LUCAR-G39D, in oral presentations at the ASH Annual Meeting. For details, please refer to the press release as published on Legend's website available at https://investors.legendbiotech.com//news-releases/news-release-details/legend-biotech-highlights-new-carvyktir-data-multiple-myeloma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this announcement about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend's strategies and objectives, statements relating to CARVYKTI® and LUCAR-G39D, including Legend Biotech's expectations for CARVYKTI®, LUCAR-G39D and their therapeutic potential; statements related to the potential results from ongoing studies in the CARTITUDE and LUCAR-G39D clinical development programs; and the potential benefits of Legend's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend's third party partners; uncertainties arising from challenges to Legend's patent or other proprietary intellectual

property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend's Annual Report on Form 20-F filed with the Securities and Exchange Commission on 11 March 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement as anticipated, believed, estimated or expected. Any forward-looking statements contained in this announcement speak only as of the date of this announcement. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 7 December 2025

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu, and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi ("**Dr. Victor Shi**").*